Adult Dosing
Osteoarthritis
- 1200 mg PO Daily
- Max: 1800 mg/day
Rheumatoid Arthritis
- 1200 mg PO Daily
- Max: 1800 mg/day or 26 mg/kg/day
Note:
- Use the lowest effective dose for the shortest duration
Pediatric Dosing
Juvenile Rheumatoid Arthritis (6-16 yrs)
- 22-31 kg body weight: 600 mg PO Daily
- 32-54 kg body weight: 900 mg PO Daily
- >55 kg body weight: 1200 mg PO Daily
- Max: 1200 mg/day
Note:
- Use the lowest effective dose for the shortest duration
[Outline]
- Risk of serious and potentially fatal cardiovascular thrombotic events, MI, and stroke are associated with NSAIDs. This risk can be minimized with the use of lowest effective dose of NSAIDs for shortest duration of time [US Black Box Warning]
- Increases risk of serious, fatal GI adverse events including bleeding, ulceration, and stomach or intestine perforation. Such events may occur at any time during use and without any warnings or symptoms[US Black Box Warning]
- Increased risk of serious GI events can occur on concurrent use of aspirin and an NSAID
- Onset of new hypertension or worsening of preexisting hypertension has been reported with NSAIDs therapy. Use cautiously in patients with hypertension and closely monitor the blood pressure before starting the therapy and periodically throughout the course of therapy
- Fluid retention and edema have been reported in some patients taking this therapy; use cautiously in patients with fluid retention or heart failure
- Use cautiously in patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding as they are 10-fold increased risk for developing a GI bleed. However risk of GI bleeding can also be increased with concomitant use of oral corticosteroids or anticoagulants, prolong use of NSAID therapy, smoking, and use of alcohol, older age, and poor general health status. Consider alternate therapy for high risk patients
- Prolong administration of this therapy can lead to renal papillary necrosis and other renal injury. Renal toxicity was observed in patients in whom renal prostaglandins have a role in the maintenance of renal perfusion. Patients with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly are at higher risk. It recovers to the pretreatment state on discontinuation of therapy
- Therapy is not recommended in patients with advanced kidney disease. However, if therapy is initiated, closely monitor patient’s kidney function
- Anaphylactoid reactions have been reported in patients without known prior exposure to therapy. Avoid using this drug in patients with the aspirin triad or a history of angioedema
- Fatal and serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN) may occur with this therapy, if such events occur use of the drug should be discontinued
- Avoid use in late pregnancy as oxaprozin may cause premature closure of the ductus arteriosus
- Oxaprozin may cause borderline elevations of one or more liver tests, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, has been reported in some patients. Discontinue the treatment if sign and symptoms of liver diseases occurs
- Anemia has been reported in some patients receiving NSAIDs. This may be due to fluid retention, occult or gross GI blood loss. Check hemoglobin or hematocrit regularly in patients on long term therapy with NSAIDs
- NSAIDs inhibit platelet aggregation and prolong the bleeding time in some patients. Patients with coagulation disorders or receiving anticoagulants are at higher risk
- Photosensitivity reactions with UV light
Cautions: Use cautiously in
- Severe renal impairment
- Severe hepatic impairment
- Cardiovascular disorder
- Risk of cardiac diseases
- Hypertension
- CHF
- Preexisting asthma, risk of severe and potentially fatal bronchospasm
- History GI bleed or PUD
- GI bleed or PUD risk
- Coagulation disorder
- Anticoagulant use
- Fluid retention
- Corticosteroid use
- Alcohol abuse
- Smoking
- Prolong use
- Elderly or debilitated patients
Pregnancy Category:C
Breastfeeding: No publish data available on oxaprozin during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 10 June 2011). As per manufacturer's data excreted in the milk of rats; Because of the potential for possible serious adverse reactions in nursing infants a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Daypro 600 MG TABS [Bottle] (PFIZER U.S.)
60 mg = $207
180 mg = $599.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
